A next-generation, multitarget stool DNA test, known as the next-generation Cologuard, has demonstrated a 94% sensitivity and 91% specificity in detecting colorectal cancer, surpassing the performance of fecal immunochemical testing (FIT). Thomas F. Imperiale, MD, from Indiana University Medical Center, highlighted that this version of Cologuard differs from FIT due to its unique markers, which are all methylated DNA markers. In the BLUE-C study, which involved 26,758 participants, the next-generation Cologuard showed a higher likelihood of detecting cancer (94% vs. 67%) and precancerous lesions (43% vs. 23%) compared to FIT. Imperiale emphasized the significance of the improved specificity, which is expected to reduce false positives by 30% without compromising sensitivity. This enhanced specificity will lead to fewer unnecessary follow-up colonoscopies and reduce patient anxiety.
- The next-generation Cologuard test was significantly more effective in detecting cancer and precancerous lesions compared to FIT.
- The test’s improved specificity is anticipated to reduce false positive rates by 30%.
- Future research may focus on evaluating the cost-effectiveness of the test and its acceptance among patients and providers.